Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis

NCT03274375 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Anti-NMDAR Encephalitis

Interventions

DRUG: IA session
DRUG: Rituximab

Sponsor

Assistance Publique - Hôpitaux de Paris